Aktienanalyse wird geladen …
DXCM · NASDAQ · Medical Devices · USA
87,48 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 4,66 Mrd. | 836,3 Mio. | 2,09 $ | 405,5 Mio. | 1,8 Mio · 0,4 % | 9 Mio · 2,2 % | 60,1 % | 17,9 % | 2,66 $ | 0,39 $ | — |
| 2024 | 4,03 Mrd. | 576,2 Mio. | 1,42 $ | 412,7 Mio. | 1,9 Mio · 0,5 % | 14,7 Mio · 3,6 % | 60,5 % | 14,3 % | 1,53 $ | 0,41 $ | — |
| 2023 | 3,62 Mrd. | 541,5 Mio. | 1,30 $ | 425,5 Mio. | 1,7 Mio · 0,4 % | 3,7 Mio · 0,9 % | 63,2 % | 15 % | 1,20 $ | 0,35 $ | — |
| 2022 | 2,91 Mrd. | 341,2 Mio. | 0,82 $ | 427,5 Mio. | 1,4 Mio · 0,3 % | 2,7 Mio · 0,6 % | 64,7 % | 11,7 % | 0,71 $ | 0,30 $ | — |
| 2021 | 2,45 Mrd. | 216,9 Mio. | 0,53 $ | 428,8 Mio. | 1,3 Mio · 0,3 % | — | 68,6 % | 8,9 % | 0,12 $ | 0,26 $ | — |
| 2020 | 1,93 Mrd. | 549,7 Mio. | 1,33 $ | 420,4 Mio. | 1,4 Mio · 0,3 % | — | 66,4 % | 28,5 % | 0,66 $ | 0,28 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,31 Mrd. | 249,1 Mio. | 0,64 $ | 390,1 Mio. | 63,4 % | 19 % | 0,47 $ |
| Q1 2026 | 1,19 Mrd. | 199,5 Mio. | 0,51 $ | 393,6 Mio. | 63 % | 16,7 % | 1,14 $ |
| Q4 2025 | 1,26 Mrd. | 267,3 Mio. | 0,66 $ | 398,9 Mio. | 62,9 % | 21,2 % | 0,47 $ |
| Q3 2025 | 1,21 Mrd. | 283,8 Mio. | 0,70 $ | 407,4 Mio. | 60,5 % | 23,5 % | 1,42 $ |
| Q2 2025 | 1,16 Mrd. | 179,8 Mio. | 0,44 $ | 408,2 Mio. | 59,5 % | 15,5 % | 0,51 $ |
| Q1 2025 | 1,04 Mrd. | 105,4 Mio. | 0,26 $ | 407,5 Mio. | 56,9 % | 10,2 % | 0,24 $ |
| Q4 2024 | 1,11 Mrd. | 151,7 Mio. | 0,37 $ | — | 58,9 % | 13,6 % | 0,44 $ |
| Q3 2024 | 994,2 Mio. | 134,6 Mio. | 0,33 $ | 410,2 Mio. | 59,7 % | 13,5 % | 0,22 $ |
Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?
DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer
Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key Players
Truist Securities Adjusts DexCom Price Target to $102 From $93, Maintains Buy Rating
Dexcom Insider Sold Shares Worth $679,769, According to a Recent SEC Filing
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest DXCM und jede andere Aktie unbegrenzt.